{"id":"dmards-or-biologics","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Lipid elevations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"DMARDs or Biologics, such as Tocilizumab, work by inhibiting the co-stimulation of T-cells, thereby reducing inflammation and autoimmune responses.","oneSentence":"T-cell co-stimulation inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:37.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Polyarticular Juvenile Idiopathic Arthritis"}]},"trialDetails":[{"nctId":"NCT07489326","phase":"","title":"The SetPoint System Safety & Performance Post-Approval Study","status":"NOT_YET_RECRUITING","sponsor":"SetPoint Medical Corporation","startDate":"2026-04-15","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT07286058","phase":"PHASE3","title":"Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-03-11","conditions":"Psoriatic Arthritis","enrollment":1182},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07417995","phase":"","title":"A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Royal United Hospitals Bath NHS Foundation Trust","startDate":"2026-03","conditions":"Psoriasis Arthritis","enrollment":400},{"nctId":"NCT06382051","phase":"NA","title":"Modifying PEST for Psoriatic Arthritis Screening","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-01-23","conditions":"Plaque Psoriasis, Psoriatic Arthritis","enrollment":502},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT06718569","phase":"","title":"Pain in Inflammatory Joint Diseases","status":"NOT_YET_RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2025-08","conditions":"Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid","enrollment":350},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT06945666","phase":"PHASE4","title":"A Study of Iguratimod in Combination With Tofacitinib in RA Patients","status":"NOT_YET_RECRUITING","sponsor":"Jie Chang","startDate":"2025-08-01","conditions":"Rheumatoid Arthritis (RA","enrollment":200},{"nctId":"NCT03531073","phase":"","title":"Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Psoriatic Arthritis","enrollment":446},{"nctId":"NCT01932372","phase":"","title":"Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07-26","conditions":"Rheumatoid Arthritis","enrollment":9968},{"nctId":"NCT05291819","phase":"NA","title":"Imaging Treat-to-target Strategy vs Conventional Treat-to-target Strategy in Psoriatic Arthritis","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2022-03-14","conditions":"Psoriatic Arthritis","enrollment":202},{"nctId":"NCT04748939","phase":"PHASE4","title":"Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT","status":"NOT_YET_RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2025-01","conditions":"Herpes Zoster","enrollment":140},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT06417138","phase":"","title":"Comparative Effectiveness of Different Drugs Used to tr€at Patients in Rheumatoid Arthritis Saudi Database (RASD)\"","status":"RECRUITING","sponsor":"Umm Al-Qura University","startDate":"2023-12-15","conditions":"Rheumatoid Arthritis RA","enrollment":800},{"nctId":"NCT06306339","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2024-03","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT05545020","phase":"PHASE2, PHASE3","title":"Trivalent Chromium Treatment for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-12-25","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04749160","phase":"","title":"Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-06-04","conditions":"Rheumatoid Arthritis","enrollment":26},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT06020144","phase":"PHASE3","title":"A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs","status":"UNKNOWN","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-11-15","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT01844518","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-30","conditions":"Active Polyarticular Juvenile Idiopathic Arthritis","enrollment":219},{"nctId":"NCT05683769","phase":"","title":"microRNA in Erosive Hand Osteoarthritis and Psoriatic Arthritis","status":"COMPLETED","sponsor":"University of Siena","startDate":"2018-09-01","conditions":"Erosive Osteoarthritis, Psoriatic Arthritis","enrollment":150},{"nctId":"NCT02706847","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-15","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT04434885","phase":"","title":"Axial Involvement in Psoriatic Arthritis Cohort","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2021-07-01","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT01490450","phase":"PHASE2","title":"Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-12","conditions":"Arthritis, Psoriatic","enrollment":165},{"nctId":"NCT03131661","phase":"","title":"A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2017-06-09","conditions":"Spondyloarthritis, Axial and Peripheral","enrollment":351},{"nctId":"NCT03011242","phase":"","title":"DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2017-01-11","conditions":"Psoriatic Arthritis","enrollment":47},{"nctId":"NCT05001672","phase":"PHASE4","title":"The Efficacy of Prophylactic TAF for HBsAg-positive Patients Receiving bDMARDs","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2021-08-15","conditions":"HBV, Inflammatory Arthritis","enrollment":108},{"nctId":"NCT02627768","phase":"","title":"A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2015-12-17","conditions":"Psoriatic Arthritis","enrollment":991},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03797872","phase":"PHASE4","title":"Psoriatic Oligoarthritis Intervention With Symptomatic thErapy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-04-17","conditions":"Psoriatic Arthritis","enrollment":1},{"nctId":"NCT03682705","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":242},{"nctId":"NCT01387802","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-06-29","conditions":"Ankylosing Spondylitis","enrollment":722},{"nctId":"NCT01559038","phase":"","title":"Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02-16","conditions":"Psoriatic Arthritis","enrollment":483},{"nctId":"NCT03073109","phase":"","title":"Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-03-15","conditions":"Arthritis, Rheumatoid","enrollment":170},{"nctId":"NCT01095393","phase":"","title":"National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09-01","conditions":"Rheumatoid Arthritis","enrollment":12500},{"nctId":"NCT02349295","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-12-31","conditions":"Psoriatic Arthritis","enrollment":363},{"nctId":"NCT04449224","phase":"","title":"Comparative Effectiveness of Targeted Therapy in RA Patients","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2020-04-27","conditions":"Rheumatoid Arthritis","enrollment":506},{"nctId":"NCT02584855","phase":"PHASE3","title":"A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-09-14","conditions":"Psoriatic Arthritis","enrollment":394},{"nctId":"NCT04139954","phase":"","title":"Observational Registry of Patients With Rheumatoid Arthritis /Spondyloarthritis Using Biological or Targeted Synthetic DMARDs","status":"UNKNOWN","sponsor":"Turkish League Against Rheumatism","startDate":"2019-02-01","conditions":"Rheumatoid Arthritis, Spondyloarthritis","enrollment":1400},{"nctId":"NCT03330769","phase":"","title":"Ultrasound in Psoriatic Arthritis Treatment","status":"UNKNOWN","sponsor":"University of Cagliari","startDate":"2017-02-03","conditions":"Arthritis, Psoriatic, Ultrasonography, Minimal Disease, Residual","enrollment":250},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT01407419","phase":"NA","title":"The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population","status":"COMPLETED","sponsor":"CorEvitas","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":538},{"nctId":"NCT03508713","phase":"","title":"Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-05-13","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT01362062","phase":"","title":"Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10-26","conditions":"Rheumatoid Arthritis","enrollment":110},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00443651","phase":"PHASE3","title":"A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-01","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT01033656","phase":"PHASE2","title":"Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"2005-12","conditions":"Adult-Onset Still's Disease","enrollment":23},{"nctId":"NCT01791205","phase":"","title":"ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":304},{"nctId":"NCT02011334","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07","conditions":"Rheumatoid Arthritis","enrollment":285},{"nctId":"NCT01149057","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-10","conditions":"Rheumatoid Arthritis","enrollment":145},{"nctId":"NCT01783730","phase":"","title":"Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02","conditions":"Rheumatoid Arthritis","enrollment":163},{"nctId":"NCT01578850","phase":"PHASE4","title":"Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":491},{"nctId":"NCT01717846","phase":"PHASE4","title":"Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2012-12","conditions":"Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis","enrollment":""},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT01015547","phase":"PHASE3","title":"Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2003-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00750880","phase":"PHASE3","title":"An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":1681},{"nctId":"NCT01106079","phase":"PHASE3","title":"TIght COntrol of Psoriatic Arthritis","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2008-05","conditions":"Psoriatic Arthritis","enrollment":206},{"nctId":"NCT02434757","phase":"NA","title":"Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Ronald J. Rapoport, MD","startDate":"2014-02","conditions":"Rheumatoid Arthritis","enrollment":10},{"nctId":"NCT01254331","phase":"PHASE3","title":"An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":51},{"nctId":"NCT01195272","phase":"PHASE4","title":"A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08","conditions":"Rheumatoid Arthritis","enrollment":21},{"nctId":"NCT00883753","phase":"PHASE3","title":"An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":934},{"nctId":"NCT01001182","phase":"","title":"Health Outcomes in Rheumatoid Arthritis in Greece","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Rheumatoid Arthritis","enrollment":210},{"nctId":"NCT01089023","phase":"PHASE4","title":"A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":95},{"nctId":"NCT01499732","phase":"","title":"Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects","status":"COMPLETED","sponsor":"Orrin M Troum, M.D. and Medical Associates","startDate":"2011-12","conditions":"Premature Endothelial Dysfunction, Rheumatoid Arthritis, Healthy","enrollment":15},{"nctId":"NCT01835613","phase":"PHASE4","title":"Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.","status":"UNKNOWN","sponsor":"Osservatorio Epidemiologico GISEA","startDate":"2013-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":150},{"nctId":"NCT00396812","phase":"PHASE1, PHASE2","title":"Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-11","conditions":"Rheumatoid Arthritis","enrollment":4},{"nctId":"NCT00891020","phase":"PHASE3","title":"A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-05","conditions":"Rheumatoid Arthritis","enrollment":886},{"nctId":"NCT00124982","phase":"PHASE3","title":"Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1286},{"nctId":"NCT00780793","phase":"PHASE4","title":"Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-09","conditions":"Rheumatoid Arthritis","enrollment":250},{"nctId":"NCT00048932","phase":"PHASE3","title":"A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":1795},{"nctId":"NCT01083693","phase":"","title":"Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-09","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":162},{"nctId":"NCT00929357","phase":"","title":"Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-08","conditions":"Rheumatoid Arthritis","enrollment":156},{"nctId":"NCT01137851","phase":"","title":"Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-11","conditions":"Rheumatoid Arthritis","enrollment":3940}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":552069,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DMARDs or Biologics","genericName":"DMARDs or Biologics","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"T-cell co-stimulation inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Polyarticular Juvenile Idiopathic Arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}